Navigation Links
Gene Tests Match Up Lung Tumors, Best Treatment
Date:10/3/2007

DNA indicates whether chemo will work, experts say

WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a lung tumor's genetic profile may help doctors determine the best chemotherapy for patients, U.S. research suggests.

"We were able to predict which tumors would be most likely to respond to standard first-line therapy and which would respond better to what has traditionally been a second-line therapy, based on gene expression profiling," lead author and oncologist Dr. David Hsu, of Duke University in Durham, N.C., said in a prepared statement.

"This represents a big step in the move toward individualized medicine," he said. "This could also make a huge difference in the treatment of patients with late-stage lung cancer, as most of these patients gain the most benefit from their initial treatment strategy."

The findings are published in the Oct. 1 issue of the Journal of Clinical Oncology.

The researchers determined that there are distinct differences in lung tumors' susceptibility to chemotherapy drugs.

In the first part of the study, Hsu's team found that certain genes expressed in non-small cell lung cancer (NSCLC) tumors known to be sensitive to cisplatin (the most commonly-used agent in the treatment of lung cancer) were not expressed in tumors known to be resistant to cisplatin. They also found that genes expressed in the tumors resistant to cisplatin were expressed in tumors sensitive to it.

In the next phase of the research, the team examined a number of second-line therapies for lung cancer, including pemetrexed, which uses a different mechanism of action to fight NSCLC tumors.

"We found the strongest inverse correlation between tumors that were sensitive to cisplatin and those that were sensitive to pemetrexed," senior author and oncologist Dr. Anil Potti said in a prepared statement. "This suggests that some patients who are not likely to respond to cisplatin should perhaps be treated with pemetrexed first."

The findings have formed the basis of a clinical trial -- the first of its kind in lung cancer -- currently being conducted at Duke University.

"These are not experimental drugs; we know they work. It's just a matter of giving each patient the right one on the first try," Potti said.

More information

The American Medical Association has more about lung cancer.



-- Robert Preidt



SOURCE: Duke University, news release, Sept. 28, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. IMA wants members not to do sex determination tests during pregnancy
2. Doctors advice early anemia tests
3. Early diagnosis for autism from blood tests may be possible
4. FDA approves Phase 0 trial which tests experimental drugs on humans
5. Genetic tests for cancer
6. Space research leads to needle-free blood tests
7. The Effectiveness Of Screening Tests Questioned
8. Blood Tests Can Help Detect Osteoporosis Early In Life
9. Easier Tests To Detect Tuberculosis
10. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
11. Skin tests confirms cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and medical ... which launched October 17, 2016, features comprehensive information regarding a wide range of ... and patients can discover the latest clinical dermatology treatments for medical skin concerns ...
(Date:12/7/2016)... ... 2016 , ... Texas Premier Locksmith , a leading ... unethical locksmith companies and is urging Search Engines to improve verification methods in ... Locksmith, these fraudulent locksmith services take advantage of consumers locked out of houses, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to ... Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip ... zones. Editors can select from a variety of flip book animations. In Addition, users ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin ... has a team of three acupuncturists to help patients realize their family building ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from My ... the reader to be aware of God's direction in their lives. “Walking With God: ... retired teacher and active church leader. , Sanford says, “I enjoy sharing ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , December 7, 2016 ... Market Research titled , Global Market Study on Multiplex Detection ... 2024 , the global multiplex detection immunoassay market is expected ... period 2016-2024. ... , , ...
(Date:12/7/2016)... FRANCISCO , December 7, 2016 ... expected to reach a value of USD 3.9 ... by Grand View Research, Inc. The growth of ... of donor and continuous technological advancements by the ... increasing continuously due to increasing donation, rising awareness ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC announced ... recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and ... same target on B cells as Rituxan and maintains ... but is also involved in tumor targeting, engagement of ... effect. The results of the study (abstract #95954) were ...
Breaking Medicine Technology: